Clinical Trial

Semaglutide vs Sitagliptin

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled Diabetes Mellitus.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-01-13; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Enrolling by Invitation 2022-11-07
Trial Details
NCT Number NCT05195944
Lead Sponsor University Health Network, Toronto
Collaborators: Novo Nordisk A/S
Conditions Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
Enrollment 58 participants
Start Date 2022-10-26
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06